PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a prominent global biopharmaceutical company specializing in innovative specialty care, has announced robust sales figures for the first quarter of 2025. The company reported a remarkable total sales growth of 11.6% at constant exchange rates (CER) and 11.7% as reported. This surge in revenue was driven by strong performance across all three of its therapeutic areas: Oncology, Neuroscience, and Rare Disease, with notable contributions from its innovative products, Iqirvo and Bylvay.

The quarterly sales summary shows that:

  • Oncology: 655.0 million with an 8.5% increase
  • Neuroscience: 193.5 million with an 8.0% increase
  • Rare Disease: 70.3 million, showcasing a staggering growth of 78.4%
  • Total Sales: 918.8 million, reflecting an overall increase of 11.7%

David Loew, Chief Executive Officer of Ipsen, commented on the impressive results, stating, "Ipsen has delivered a strong start to 2025, building further momentum in the transformation of our company. We continued to execute on our strategy with strong top-line growth and pipeline progression. I am pleased to see the rapid build-up of our Rare Cholestatic Liver disease franchise with two innovative medicines for five indications. 2025 is set to be an important year for Ipsen, with multiple launches underway and several milestones expected across our portfolio."

Full-Year Guidance
Ipsen has reaffirmed its financial guidance for the full year of 2025, expecting total sales growth to exceed 5.0% at constant currency. Based on March 2025's average exchange rates, the company anticipates only a minimal impact from currency fluctuations on total sales.

The company also aims for a core operating margin greater than 30.0% of total sales, which includes expected increases in research and development (R&D) expenses due to anticipated early-stage and mid-stage external-innovation opportunities. It is important to note that the guidance takes into account the expected negative impact on Somatuline sales stemming from increased generic competition in both the U.S. and Europe, which could affect total revenue.

Upcoming Milestones
Ipsen is gearing up for several key milestones in 2025, which include:

  • Cabometyx (CABINET trial): A regulatory decision in the European Union regarding advanced pancreatic neuroendocrine tumors (pNETs) and extra-pancreatic neuroendocrine tumors (epNETs).
  • fidrisertib (FALKON trial): Readout of the pivotal Phase IIb trial for fibrodysplasia ossificans progressiva (FOP).
  • LANT3 (LANTIC trial): Proof-of-concept data readout evaluating its potential in aesthetics.

Q1 Pipeline Progress
In terms of pipeline developments, the regulatory filing for tovorafenib has been accepted by the European Medicines Agency (EMA) for review. This marks a significant advancement in the development of this prospective treatment for pediatric low-grade glioma, underscoring Ipsen's commitment to innovation in addressing rare and challenging cancers. Additionally, Ipsen has initiated Phase I trials for IPN01195, a RAF inhibitor, which will complement its existing IPN01194, an ERK inhibitor, and tovorafenib, both of which target the MAPK pathway.

Group Refinancing
On March 19, Ipsen successfully completed its inaugural Rated Public Bond issuance, amounting to 500 million with a coupon rate of 3.875%, maturing in March 2032. This transaction was well-received and oversubscribed by a diverse group of institutional investors following the positive Investment Grade ratings from both S&P and Moodys. This financing initiative is a crucial component of Ipsen's broader refinancing plan, which also included the renewal of a 1.5 billion syndicated Revolving Credit Facility, effectively extending the companys debt maturity profile.

Conference Call
Ipsen is set to hold a conference call and webcast for investors and analysts today at 2 PM CET. Interested parties can access the call by registering through the provided links.

Upcoming Calendar Events
Ipsen plans to publish its half-year results on July 31, 2025.

About Ipsen
Ipsen is a global biopharmaceutical company dedicated to delivering transformative medicines in three primary therapeutic areas: Oncology, Rare Disease, and Neuroscience. With nearly a century of innovation and development experience, Ipsen operates in over 40 countries and is committed to bringing advanced medical solutions to patients worldwide. The company is listed on the Paris stock exchange (Euronext: IPN) and participates in the U.S. market through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit